DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 208 filers reported holding DENALI THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $3,475 | -64.0% | 161,946 | -65.4% | 0.01% | -68.8% |
| Q3 2023 | $9,652 | -30.1% | 467,851 | +0.0% | 0.02% | -20.0% |
| Q2 2023 | $13,805 | +46.8% | 467,800 | +14.6% | 0.02% | +66.7% |
| Q1 2023 | $9,403 | +35.5% | 408,100 | +63.5% | 0.01% | +33.3% |
| Q4 2022 | $6,941 | -99.9% | 249,600 | -36.4% | 0.01% | -47.1% |
| Q3 2022 | $12,037,000 | +61.3% | 392,200 | +54.7% | 0.02% | +88.9% |
| Q2 2022 | $7,461,000 | +89.2% | 253,500 | +106.8% | 0.01% | +80.0% |
| Q1 2022 | $3,944,000 | +62.8% | 122,600 | +125.8% | 0.01% | +66.7% |
| Q4 2021 | $2,422,000 | -49.8% | 54,300 | -43.2% | 0.00% | -50.0% |
| Q3 2021 | $4,823,000 | +434.7% | 95,600 | +731.3% | 0.01% | +500.0% |
| Q2 2021 | $902,000 | -94.1% | 11,500 | -95.7% | 0.00% | -94.7% |
| Q1 2021 | $15,183,000 | +722.9% | 265,900 | +416.3% | 0.02% | +850.0% |
| Q3 2020 | $1,845,000 | +41.1% | 51,500 | -18.3% | 0.00% | +100.0% |
| Q2 2019 | $1,308,000 | – | 63,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |